BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  05/20 04:00:01 pm EDT
252.30 USD   +0.46%
05/19BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partnership agreement to explore new ways to advance biologic drug delivery
AQ
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales Outlook
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
252.89(c) 256.26(c) 251.1(c) 251.14(c) 252.3(c) Last
1 126 314 1 000 617 899 245 1 234 586 910 923 Volume
+1.79% +1.33% -2.01% +0.02% +0.46% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 18 743 M - -
Net income 2022 1 746 M - -
Net Debt 2022 13 463 M - -
P/E ratio 2022 35,1x
Yield 2022 1,51%
Sales 2023 19 398 M - -
Net income 2023 1 981 M - -
Net Debt 2023 11 816 M - -
P/E ratio 2023 29,4x
Yield 2023 1,61%
Capitalization 71 922 M 71 922 M -
EV / Sales 2022 4,56x
EV / Sales 2023 4,32x
Nbr of Employees 75 000
Free-Float 77,6%
More Financials
Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (46.8%): surgical instruments (25.7% of net sales), pharmaceutical systems (19.3%), diabetes care products (12.2%), and other (42.8%); - diagnostic materials (32.3%): automated systems for blood... 
More about the company
Ratings of Becton, Dickinson and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about BECTON, DICKINSON AND COMPANY
05/19BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partne..
AQ
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales..
MT
05/12BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Pl..
PR
05/12Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Dise..
CI
05/11TRANSCRIPT : Becton, Dickinson and Company Presents at Bank of America 2022 Healthcare Con..
CI
05/11Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New C..
PR
05/11Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collect..
CI
05/10INSIDER SELL : Becton Dickinson
MT
05/06Piper Sandler Adjusts Price Target on Becton Dickinson and Co. to $255 From $265, Maint..
MT
05/05BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
05/05TRANSCRIPT : Becton, Dickinson and Company, Q2 2022 Earnings Call, May 05, 2022
CI
05/05Stocks Signal Weaker Opening as Futures Trade Lower Pre-Bell; Asia Mixed, Europe Higher
MT
05/05Wall Street Leans Back Pre-Bell; Futures Red, Europe Up, Asia Muted
MT
05/05Becton, Dickinson Fiscal Q2 Adjusted Earnings Drop, Revenue Rises; Company Lowers FY22 ..
MT
More news
News in other languages on BECTON, DICKINSON AND COMPANY
05/13Embecta voit ses résultats du deuxième trimestre fiscal chuter en raison de vents contr..
05/12Becton, Dickinson and Company lance aux États-Unis une plateforme de diagnostic molécul..
05/11Babson Diagnostics et BD étendent leur partenariat stratégique pour faire progresser le..
05/10VENTE PAR DES INITIÉS : Becton Dickinson
05/05Les actions signalent une ouverture plus faible alors que les Futures s'échangent à la ..
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 252,30 $
Average target price 283,08 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY2.66%71 922
ABBOTT LABORATORIES-19.54%198 277
MEDTRONIC PLC-0.89%137 548
HOYA CORPORATION-22.41%37 902
BAXTER INTERNATIONAL INC.-14.69%36 873
DEXCOM, INC.-40.18%31 521